Ann: Appendix 3Y - Dr Daniel Tillett, page-15

I was lazy originally, hope this clarifies my point.

19.5.21 3y Dr T

20.5.21 Pro Michael Kelso appointed as principal scientist

2.6.21 contract to commence phase 2 EMD AML

13.12.21 3y

17.12.21 3y

21.12.21 RAC raises $29.7 mill in oversubscribed spp

4.3.22 3y

10.3.21 compelling zantrene pre clinical kidney cancer data

16.5.22 3y
18.5.22 Guy Breitenbucher joins SAB
26.5.22 trading halt
27.5.22 zantrene AML trial in Israel advances to phase 2

26.9.22 3y
27.9.22 RAC initiates new drug discovery program
28.9.22 RAC develops improved IV formulation

7.10.22 3y
18.10.22 investor presentation for microcap conference

8.11.22 3y
11.11.22 CMO appointment

14.11.22 3y
23.11.22 positive pre IND guidance from FDA on zantrene

21.12.22 3y
22.12.22 RAC supports study of EMD AML

16.1.23 3y Dr T
What comes next ????

Good luck to all associated with RAC.